Vinorelbine Ditartrate
Exocrine Pancreatic Carcinoma
Floatz Rating
BB67/100
Confidence
Indicative
Sponsor
OHSU Knight Cancer Institute
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
52High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05238831CT.gov SMMART Adaptive Clinical Treatment (ACT) Trial | — | Withdrawn | — | — | — |
NCT02890355CT.gov FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer | — | Completed | — | — | — |
NCT00892736CT.gov Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Exocrine Pancreatic Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Vinorelbine Ditartrate (this asset) | OHSU Knight Cancer Institute | P2 | BB · 67 |
| Irinotecan | OHSU Knight Cancer Institute | P2/3 | BBB |
| Oxaliplatin | OHSU Knight Cancer Institute | P2/3 | BBB |
| Fluorouracilum | Northwestern University | P2/3 | BBB |
| Vismodegib | OHSU Knight Cancer Institute | P2 | BB |
| Capecitabine | Zhejiang University | P2 | BB |
| Carboplatin | OHSU Knight Cancer Institute | P2 | BB |
| Olaparib | National Cancer Institute (NCI) | P2 | BB |
| Cis-Diamminedichloroplatinum Ii | Alliance for Clinical Trials in Oncology | P2/3 | BB |
+42 more in the Exocrine Pancreatic Carcinoma cohort
Other indications for Vinorelbine Ditartrate
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hodgkins Lymphoma | — | P3 | BBB · 72 |
| Cervical Cancer | — | P2 | BBB · 72 |
| Non-Small Cell Lung Carcinoma | — | P4 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Vinorelbine Ditartrate in Exocrine Pancreatic Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/vinorelbine-ditartrate-exocrine-pancreatic-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →